arrow
D

Daniela Scattolin

Veneto Institute of Oncology IOV-IRCCS
H指数:6
被引数:188

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Analysis of SLFN11 expression in small cell lung cancer, carcinoids and large cell neuroendocrine carcinoma: insights into lung neuroendocrine neoplasms

SLFN11在肺小细胞癌、类癌和大细胞神经内分泌癌中的表达分析:对肺神经内分泌肿瘤的见解

2026-07-130
OAAI
CHIMERA: a phase II study of neoadjuvant pembrolizumab in combination with cisplatin or carboplatin and pemetrexed followed by surgery and adjuvant pembrolizumab in resectable pleural mesothelioma

CHIMERA:一项关于新辅助培美曲塞联合顺铂或卡铂和培美曲塞,随后进行手术及辅助培美曲塞治疗可切除胸膜间皮瘤的II期研究

2026-05-270
OAAI
Dissecting the prognostic role of metabolic markers in lung neuroendocrine Tumors: The MONET study

解析代谢标志物在肺神经内分泌肿瘤中的预后作用:MONET研究

2026-05-230
OAAI
Advanced-stage ALK-positive non–small-cell lung cancer (NSCLC) patients: Real-world treatment patterns and outcomes from the Italian biomarker ATLAS database

晚期ALK阳性非小细胞肺癌(NSCLC)患者:来自意大利生物标志物ATLAS数据库的真实世界治疗模式与结果

2025-09-240
OAAI
Advanced ALK-positive non-small cell lung cancer (NSCLC) patients: Real-world treatment patterns and outcomes from the Italian biomarker ATLAS database

晚期ALK阳性非小细胞肺癌(NSCLC)患者:来自意大利生物标志物ATLAS数据库的真实世界治疗模式与结果

2024-09-010
PRE
Real-world data on treatment outcomes in EGFR-mutant non-small-cell lung cancer patients receiving osimertinib in second or further lines
2021-05-148
OA
Clinical Features and Progression Pattern of Acquired T790M-positive Compared With T790M-negative EGFR Mutant Non-small-cell Lung Cancer: Catching Tumor and Clinical Heterogeneity Over Time Through Liquid Biopsy
2020-01-0119
PREAI